Welcome Guest
Home > Clinical Lymphoma Myeloma > Volume 7 |  Issue 4 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  Rajkumar SV,Kyle RA,Therneau TM : Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades : Cancer : 2004 : .
    2.  Hamilton A,Huang YW,Arnuk OJ : Current drug therapy for multiple myeloma : Drugs : 1999 : .
    3.  Hamilton A,Huang YW,Arnuk OJ : Going APE over ref-1 : Mutat Res : 2000 : .
    4.  Hamilton A,Huang YW,Arnuk OJ : Two distinct human DNA diesterases that hydrolyze 3´-blocking deoxyribose fragments from oxidized DNA : Nucleic Acids Res : 1991 : .
    5.  Hamilton A,Huang YW,Arnuk OJ : Human APE/Ref-1 protein : Int J Biochem Cell Biol : 2000 : .
    6.  Hamilton A,Huang YW,Arnuk OJ : Redox regulation of the DNA repair function of the human AP endonuclease Ape1/ref-1 : Antioxid Redox Signal : 2001 : .
    7.  Zhu C,Jayaraman L,Murthy KGK : Identification of redox/repair protein Ref-1 as a potent activator of p53 : Genes Dev : 1997 : .
    8.  Zhu C,Jayaraman L,Murthy KGK : Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition : Mol Cancer Ther : 2004 : .
    9.  Ribatti D,Bernardini G,Spinetti G : Analysis of the role of chemokines in angiogenesis : J Immunol Methods : 2003 : .
    10.  Davis M,Thomson B,Tritt R : Histology-specific expression of a DNA repair protein in pediatric rhabdomyosarcomas : Am J Pediatr Hematol Oncol : 2001 : .
    11.  Moore DH,Tritt R,Michael H : Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers : Clin Cancer Res : 2000 : .
    12.  Moore DH,Xu Y,Broshears J : The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer : Anticancer Res : 1997 : .
    13.  Cheng L,Foster R,Kelley MR : Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer : Clin Cancer Res : 2001 : .
    14.  Puglisi F,Barbone F,Tell G : Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas : Oncol Rep : 2002 : .
    15.  Xu Y,Robertson KA,Bullock HA : Altered expression of Ape1/ ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation : Cancer Res : 2001 : .
    16.  Puglisi F,Aprile G,Minisini AM : Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas : Anticancer Res : 2001 : .
    17.  Puglisi F,Aprile G,Minisini AM : A system for stable expression of short interfering RNAs in mammalian cells : Science : 2002 : .
    18.  Puglisi F,Aprile G,Minisini AM : RNA interference is mediated by 21- and 22-nucleotide RNAs : Genes Dev : 2001 : .
    19.  Diaz RM,Dingli D,Bergert ER : Genetically targeted radiotherapy for multiple myeloma : Blood : 2003 : .
    20.  Barlogie B,Zangari M,Bolejack V : Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma : Clin Lymphoma Myeloma : 2006 : .
    21.  Elice F,Raimondi R,Tosetto A : Prolonged overall survival with second on-demand autologous transplant in multiple myeloma : Am J Hematol : 2006 : .
    22.  Itala M,Jantumen E,Lehtinen T : Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients : Eur J Haematol : 2006 : .
    23.  Chauhan D,Hideshima T,Richardson P : Identification and validation of novel therapeutic targets for multiple myeloma : J Clin Oncol : 2005 : .
    24.  Chatterjee M,Hildebrandt M,Stuhmer T : Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma : Blood : 2005 : .
    25.  Richardson PG,Mitsiades CS,Hideshima T : Novel biological therapies for the treatment of multiple myeloma : Best Pract Res Clin Haematol : 2005 : .
    26.  Richardson PG,Mitsiades CS,Hideshima T : Extracellular matrix in bone marrow can mediate drug resistance in myeloma : Leuk Lymphoma : 2005 : .
    27.  Chauhan D,Hideshima T,Podar K : Targeting signalling pathways for the treatment of multiple myeloma : Expert Opin Ther Targets : 2005 : .
    28.  Lin B,Tai YT,Teoh G : Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage : J Immunol : 2000 : .
    29.  Vitelli G,Greco C,D’Agnano I : c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB : Int J Immunopathol Pharmacol : 2006 : .
    30.  Alsina M,Nefedova Y,Cheng P : Involvement of Notch-1 signaling in bone marrow stroma- mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines : Blood : 2004 : .
    31.  Shi Y,Hu L,Gera J : Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 : Cancer Res : 2002 : .
    32.  Craddock C,Spanswick VJ,Sekhar M : Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma : Blood : 2002 : .
    33.  Craddock C,Spanswick VJ,Sekhar M : Integrin-mediated drug resistance in multiple myeloma : Leuk Lymphoma : 2000 : .
    34.  Gazitt Y,Thomas C,Fev V : Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells : Int J Oncol : 1998 : .
    35.  Gazitt Y,Thomas C,Fev V : Update on the treatment of multiple myeloma : Oncologist : 2001 : .
    36.  Fawzy FI,Fawzy NW,Hyun CS,Richardson PG,Berenson J,Barlogie B,Tulpule A,Sherrod A,Dharmapala D,Herbert J,Pepys MB,Hutchinson WL,Mandalia S,Stebbing J,Gazzard B,Gazitt Y,Thomas C,Fev V : Multiple myeloma : N Engl J Med : 2004 : .
    37.  Harris AL,Walker LJ,Craig RB : A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress : Nucleic Acids Res : 1994 : .
    38.  Furuta T,Ono Y,Ohmoto T : Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease : Mutat Res : 1994 : .
    39.  Furuta T,Ono Y,Ohmoto T : Biological responses of human apurinic endonuclease to radiation-induced DNA damage : Ann NY Acad Sci : 1994 : .
    40.  Madhusudan S,Smart F,Shrimptom P : Isolation of a small molecule inhibitor of DNA base excision repair : Nucleic Acids Res : 2005 : .
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume Number 7
  •  Issue 4
    • Cover Date: January 01, 2007


Experimental Study Enhancing the Chemosensitivity of Multiple Myeloma to Melphalan by Using a Tissue-Specific APE1-Silencing RNA Expression Vector


Authors: Zhen-Zhou Yang, Xing-Hua Chen, Dong Wang

Purpose: Because of a developing resistance to chemotherapy agents, multiple myeloma (MM) has been an incurable disease until now. As a means to overcome MM tumor cell resistance and/or sensitize tumor cells to chemotherapeutic treatments currently used, we examined the role of human apurinic/apyrimidinic endonuclease 1 (APE1) in resistance and prognosis in patients with MM. Patients and Methods: Multiple myeloma cells were analyzed by using bone marrow specimens from 32 patients with MM and 10 normal volunteers. Results: The positive rate of APE1 protein expression was 65.6% in the bone marrow specimens of patients with MM with known clinical outcome. Positive rate of APE1 expression beyond grade 2 in the relapsed/refractory group was significantly higher than that in the untreated group. No positive results of grade> 2 were detected in bone marrow specimens from patients with noncancerous disease. It was also confirmed that the amount of APE1 protein in KM3 cells was positively correlated with the dose and action time of melphalan. Because APE1 was overexpressed in refractory/relapsed MM cells, siRNA-targeted technology was used to decrease APE1 levels in KM3 cells, with protein levels deceasing to 80%-90% within 24 hours and continuing to decease for 72 hours. The best dose and time of inhibiting expression of APE1 protein were 3µg and 2 days long. A decrease in APE1 levels in siRNA-treated KM3 cells led to enhanced cell sensitization to melphalan. Conclusion: The findings herein present prognostic and therapeutic implications for treating relapsed/refractory MM. The APE1-silencing RNA results demonstrate the feasibility of the therapeutic modulation of APE1 using a variety of molecules and approaches.

Keywords: Base excision repair, Bone marrow, Protein


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. Pengeluaran SDY